Brazil Drugmaker Profit Up 16% as Diet Pen Debuts
Published Tuesday, 27 October, 9:05 p.m. ET · Source: Hypera S.A. third-quarter 2026 results
Key Facts
- The numbers. Profit from ongoing businesses rose 16.1% to R$527 million (about US$98 million at 5.35 reais per dollar). Revenue rose 9.4% to R$2.44 billion (about US$456 million).
- The beat. Analysts had expected profit of R$471.4 million (about US$88 million), so Hypera landed roughly 12% above that forecast.
- The pen. Semavy, Hypera’s semaglutide pen (the Ozempic ingredient), sold about 93,000 units in September, over 11% of Brazil’s market.
- The catch. The Ebitda margin, a gauge of operating profit, slipped to 32.1% from 34%. The share reaction is not yet known.
Brazil’s rival to Ozempic, the diabetes and weight-loss drug, reached pharmacy shelves in September, and its maker has just shown the first results. Hypera, a drugmaker based in São Paulo, reported on Tuesday, 27 October, that third-quarter profit from continuing operations rose 16.1% to R$527 million (about US$98 million).
Net revenue grew 9.4% to R$2.44 billion (about US$456 million), which the company tied to stronger pharmacy sales and the start of Semavy sales. It is an early test of how fast a rival version of a blockbuster drug can grow inside Brazil’s economy.
What Hypera Reported
Hypera beat the profit and Ebitda forecasts and edged past revenue. Analysts had expected profit of R$471.4 million (about US$88 million), revenue near R$2.4 billion and Ebitda of R$772 million (about US$144 million).
Ebitda came in at R$782.3 million (about US$146 million), up 3.4% from a year earlier. Profit grew far faster than that, which we explain below.
The company is best known for household brands such as Neosaldina, a headache remedy, and Coristina, a cold medicine. Our Hypera company profile covers the business in detail.
Did the Weight-Loss Pen Launch Work?
Early signs say yes. Hypera said Semavy sold about 93,000 units in September, its first month, which was more than 11% of Brazil’s injectable semaglutide market by units.
Semavy is Hypera’s own version of semaglutide. Anvisa, Brazil’s health regulator, approved it early in the third quarter, one of several pens it has cleared, as our semaglutide race coverage reported.
One month is a thin base for a forecast. Hypera still has to show that buyers keep coming back and that rivals do not take the share it won at launch, a contest we described in our look at a Brazilian Ozempic rival.
Why Did Profit Grow Faster Than Operating Earnings?
Profit rose 16.1% while Ebitda rose 3.4%, so the margin shrank from 34% to 32.1%. That gap suggests profit got help from items below the operating line, such as interest costs.
Net debt, the money Hypera owes after subtracting its cash, fell to R$5.6 billion (about US$1.05 billion) from R$5.9 billion (about US$1.10 billion) at the end of June. Borrowing has also become cheaper as Brazil lowers its Selic interest rate, which fell to 13.75% in September.
The second quarter showed the same pattern of steady gains, with profit of R$490 million (about US$92 million) in the three months to June. Our second-quarter report has the earlier numbers.
What It Means for US Readers
Hypera’s shares trade in São Paulo under the ticker HYPE3, so dollar investors face currency risk as well as company risk. A stronger real lifts the dollar value of these profits, as our real-to-dollar guide explains.
The result also shows how local competition is reaching a drug US patients know well. Expats and visitors in Brazil may see more choice in weight-loss treatment, though they should ask a doctor before switching products.
What Is Not Known
The market has not yet priced the news, because Brazil’s stock exchange, B3, reopens at 9:00 a.m. ET on Wednesday. Hypera has not said how large the Semavy business could become over a full year.
It is also unclear how much of the quarter’s gain will repeat once launch spending and competition settle. Our Brazil stock market guide tracks Brazilian shares as they react.
Sources
Hypera S.A., investor relations · B3, São Paulo stock exchange · Anvisa, Brazil’s health regulator
This article was produced by The Rio Times’ automated newsroom system. How we use AI · Report an error · Editorial responsibility: Matthias Camenzind, Editor-in-Chief
Brazil runoff, Sunday, October 25: Brazil runoff date. Latest: Brazil runoff polls, Flávio 51%, Lula 49%.
Frequently Asked Questions
How much profit did Hypera make in the third quarter?
Hypera earned R$527 million (about US$98 million) from continuing operations, up 16.1% from a year earlier. Revenue was R$2.44 billion (about US$456 million), up 9.4%.
What is Semavy?
Semavy is Hypera’s version of semaglutide, the drug in Ozempic and Wegovy, used for diabetes and weight loss. It sold about 93,000 units in September, its first month.